1 |
van der Aa Kuhle A, Jespersen L. The taxonomic position of Saccharomyces boulardii as evaluated by sequence analysis of the D1/D2 domain of 26S rDNA, the ITS1-5.8S rDNA-ITS2 region and the mitochondrial cytochromecoxidase II gene. Syst Appl Microbiol 2003;26:564-71.
DOI
|
2 |
Center for Disease Control and Prevention/National Healthcare Safety Network. Bloodstream infection event (central line-associated bloodstream infection and noncentral line-associated bloodstream infection) [Internet]. Atlanta: Center for Disease Control and Prevention; 2016 [cited 2017 Nov 17]. Available from: http://www.cdc.gov.
|
3 |
Salminen MK, Tynkkynen S, Rautelin H, Saxelin M, Vaara M, Ruutu P, et al. Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland. Clin Infect Dis 2002;35:1155-60.
DOI
|
4 |
Salminen MK, Rautelin H, Tynkkynen S, Poussa T, Saxelin M, Valtonen V, et al. Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG. Clin Infect Dis 2004;38:62-9.
DOI
|
5 |
Munoz P, Bouza E, Cuenca-Estrella M, Eiros JM, Perez MJ, Sanchez-Somolinos M, et al. Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis 2005;40:1625-34.
DOI
|
6 |
Enache-Angoulvant A, Hennequin C. Invasive Saccharomyces infection: a comprehensive review. Clin Infect Dis 2005;41:1559-68.
DOI
|
7 |
U.S. Department of Health and Human Services, Food and Drug Administration. Investigational new drug applications (INDs): determining whether human research studies can be conducted without an IND, guidance for clinical investigators [Internet]. Silver Spring: FDA; 2013 [cited 2017 Nov 17]. Available from: https://www.fda.gov/downloads/drugs/guidances/ucm229175.pdf.
|
8 |
Cassone M, Serra P, Mondello F, Girolamo A, Scafetti S, Pistella E, et al. Outbreak of Saccharomyces cerevisiae subtype boulardii fungemia in patients neighboring those treated with a probiotic preparation of the organism. J Clin Microbiol 2003;41:5340-3.
DOI
|
9 |
Araya M, Morelli L, Reid G, Sanders ME, Stanton C. Guidelines for the evaluation of probiotics in food: report of a joint FAO/WHO working group on drafting guidelines for the evaluation of probiotics in food 2002 [Internet]. Geneva: World Health Orgarnization; 2017 [cited 2017 Nov 18]. Available from: http://www.who.int/foodsafety/fs_management/en/probiotic_guidelines.pdf.
|
10 |
Lherm T, Monet C, Nougiere B, Soulier M, Larbi D, Le Gall C, et al. Seven cases of fungemia with Saccharomyces boulardii in critically ill patients. Intensive Care Med 2002;28:797-801.
DOI
|
11 |
Mackay AD, Taylor MB, Kibbler CC, Hamilton-Miller JM. Lactobacillus endocarditis caused by a probiotic organism. Clin Microbiol Infect 1999;5:290-2.
DOI
|
12 |
Rautio M, Jousimies-Somer H, Kauma H, Pietarinen I, Saxelin M, Tynkkynen S, et al. Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG. Clin Infect Dis 1999;28:1159-60.
DOI
|
13 |
Hempel S, Newberry S, Ruelaz A, Wang Z, Miles JN, Suttorp MJ, et al. Safety of probiotics used to reduce risk and prevent or treat disease. Evid Rep Technol Assess (Full Rep) 2011;(200):1-645.
|
14 |
Oggioni MR, Pozzi G, Valensin PE, Galieni P, Bigazzi C. Recurrent septicemia in an immunocompromised patient due to probiotic strains of Bacillus subtilis. J Clin Microbiol 1998;36:325-6.
|
15 |
Boyle RJ, Robins-Browne RM, Tang ML. Probiotic use in clinical practice: what are the risks? Am J Clin Nutr 2006; 83:1256-64.
DOI
|
16 |
Hennequin C, Kauffmann-Lacroix C, Jobert A, Viard JP, Ricour C, Jacquemin JL, et al. Possible role of catheters in Saccharomyces boulardii fungemia. Eur J Clin Microbiol Infect Dis 2000;19:16-20.
DOI
|
17 |
Atici S, Soysal A, Karadeniz Cerit K, Yilmaz S, Aksu B, Kiyan G, et al. Catheter-related Saccharomyces cerevisiae fungemia following Saccharomyces boulardii probiotic treatment: in a child in intensive care unit and review of the literature. Med Mycol Case Rep 2017;15:33-5.
DOI
|
18 |
Bassetti S, Frei R, Zimmerli W. Fungemia with Saccharomyces cerevisiae after treatment with Saccharomyces boulardii. Am J Med 1998;105:71-2.
DOI
|
19 |
Mitterdorfer G, Mayer HK, Kneifel W, Viernstein H. Protein fingerprinting of Saccharomyces isolates with therapeutic relevance using one- and two-dimensional electrophoresis. Proteomics 2002;2:1532-8.
DOI
|
20 |
Wallace TC, MacKay D. The safety of probiotics: considerations following the 2011 U.S. Agency for Health Research and Quality report. J Nutr 2011;141:1923-4.
DOI
|